Talimogene laherparepvec（T-VEC）与转移性黑色素瘤的新兴瘤内免疫疗法：综述
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review.
作者信息
Kalsi Simran, Galenkamp Amanda L, Singh Rohit, Khosla Atulya Aman, McGranaghan Peter, Cintolo-Gonzalez Jessica
机构信息
Larner College of Medicine at the University of Vermont, 89 Beaumont Avenue, Burlington, VT, 05401, USA.
Department of Medicine, Division of Hematology and Oncology, University of Vermont Medical Center, 111 Colchester Avenue, Burlington, VT, 05401, USA.
出版信息
Curr Oncol Rep. 2024 Dec;26(12):1651-1663. doi: 10.1007/s11912-024-01611-9. Epub 2024 Nov 27.
Abstract
PURPOSE OF REVIEW
As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
RECENT FINDINGS
While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms. In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses. We then discuss the landscape of current and emerging intralesional therapies.
摘要
综述目的
随着皮肤黑色素瘤的发病率在全球范围内持续上升，其异质性表现给管理和预防复发带来了挑战。
最新发现
虽然手术仍然是局部区域转移性黑色素瘤分期和治疗的主要手段，但病灶内治疗已成为一种新工具，可用于治疗不可切除的移行转移灶和淋巴结转移，并通过免疫调节机制降低复发风险。在本综述中，我们将概述黑色素瘤的病灶内治疗，特别关注talimogene laherparepvec（T-VEC）及其未来用途。然后我们将讨论当前和新兴的病灶内治疗情况。
相似文献
1
Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review.Talimogene laherparepvec（T-VEC）与转移性黑色素瘤的新兴瘤内免疫疗法：综述
Curr Oncol Rep. 2024 Dec;26(12):1651-1663. doi: 10.1007/s11912-024-01611-9. Epub 2024 Nov 27.
2
Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.替莫唑胺胶囊用于治疗脑胶质瘤的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):469-473. doi: 10.1080/17425255.2018.1455825. Epub 2018 Mar 23.
3
The safety of talimogene laherparepvec for the treatment of advanced melanoma.talimogene laherparepvec治疗晚期黑色素瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.
4
Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy.联合瘤内 T-VEC 和外用咪喹莫特免疫疗法成功治疗转移性黑色素瘤。
J Immunother Cancer. 2024 Nov 19;12(11):e009581. doi: 10.1136/jitc-2024-009581.
5
An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions.替莫唑胺胶囊治疗神经胶质瘤的临床疗效及安全性评价
Am J Clin Dermatol. 2020 Dec;21(6):821-832. doi: 10.1007/s40257-020-00554-8.
6
Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.替莫唑胺（T-VEC）治疗晚期黑色素瘤：心脏和肾脏移植患者完全缓解。病例报告。
Br J Dermatol. 2019 Jul;181(1):186-189. doi: 10.1111/bjd.17783. Epub 2019 Mar 26.
7
How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.我们如何开展治疗：注射用重组人5型腺病毒（Talimogene Laherparepvec，T-VEC）瘤内免疫疗法治疗晚期黑色素瘤的管理指南
Dermatol Surg. 2020 Nov;46(11):1455-1457. doi: 10.1097/DSS.0000000000002098.
8
An evaluation of talimogene laherparepvec for the treatment of melanoma.替莫唑胺胶束治疗恶性胶质瘤的临床研究进展
Expert Opin Biol Ther. 2020 Jan;20(1):9-14. doi: 10.1080/14712598.2020.1689951.
9
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model.T-VEC 治疗 IIIB-IVM1a 期黑色素瘤可实现高完全缓解率和持久缓解率，并与肿瘤负荷相关：一项临床预测模型研究。
Cancer Immunol Immunother. 2021 Aug;70(8):2291-2300. doi: 10.1007/s00262-020-02839-7. Epub 2021 Jan 28.
10
Talimogene laherparepvec (T-VEC) as cancer immunotherapy.塔利莫基因拉罗韦克（T-VEC）作为癌症免疫疗法。
Drugs Today (Barc). 2015 Sep;51(9):549-58. doi: 10.1358/dot.2015.51.9.2383044.
引用本文的文献
1
Gene Therapies in Dermatological Diseases: A Breakthrough in Treatment.皮肤病的基因治疗：治疗上的一项突破
Int J Mol Sci. 2025 Jul 9;26(14):6592. doi: 10.3390/ijms26146592.
2
Direct transdifferentiation of tumorigenic melanoma cells induces tumor cell reversion.致瘤性黑色素瘤细胞的直接转分化诱导肿瘤细胞逆转。
Cell Death Dis. 2025 Jul 25;16(1):563. doi: 10.1038/s41419-025-07863-y.
3
Bibliometric and visual analysis of drug-specific immunotherapy from 1990 to 2024.1990年至2024年药物特异性免疫疗法的文献计量学与可视化分析
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 25. doi: 10.1007/s00210-025-04073-3.
4
Ad6-Based GM-CSF Expressing Vector Displays Oncolytic and Immunostimulatory Effects in an Immunocompetent Syrian Hamster Model of Cholangiocarcinoma.基于腺病毒6型的粒细胞-巨噬细胞集落刺激因子表达载体在具有免疫活性的叙利亚仓鼠胆管癌模型中显示出溶瘤和免疫刺激作用。
Viruses. 2025 Jan 24;17(2):162. doi: 10.3390/v17020162.
5
Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy.黑色素瘤治疗的进展：在不断发展的免疫治疗格局中对PD-1抑制剂、T-VEC、mRNA疫苗和肿瘤浸润淋巴细胞疗法的综述
J Clin Med. 2025 Feb 12;14(4):1200. doi: 10.3390/jcm14041200.
本文引用的文献
1
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.接受替莫唑胺和免疫检查点抑制剂治疗的患者皮肤免疫相关不良事件风险增加：一项多医院队列研究。
J Am Acad Dermatol. 2023 Jun;88(6):1265-1270. doi: 10.1016/j.jaad.2023.02.017. Epub 2023 Mar 21.
2
Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress.局部晚期和转移性黑色素瘤瘤内治疗的进展：五年回顾
Cancers (Basel). 2023 Feb 23;15(5):1404. doi: 10.3390/cancers15051404.
3
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.新辅助-辅助或仅辅助派姆单抗治疗晚期黑色素瘤。
N Engl J Med. 2023 Mar 2;388(9):813-823. doi: 10.1056/NEJMoa2211437.
4
Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.新辅助免疫疗法已成为最佳医疗实践，并将成为肉眼可见的III期黑色素瘤治疗的新标准。
Eur J Cancer. 2023 Mar;182:38-42. doi: 10.1016/j.ejca.2023.01.004. Epub 2023 Jan 11.
5
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.奥卡替尼和奥卡替尼-新试验中新辅助伊匹单抗加纳武单抗治疗宏观 III 期黑色素瘤的生存更新。
Ann Oncol. 2023 Apr;34(4):420-430. doi: 10.1016/j.annonc.2023.01.004. Epub 2023 Jan 18.
6
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.肿瘤内溶瘤病毒 V937 联合伊匹单抗治疗晚期黑色素瘤患者：MITCI 研究 1b 期。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005224.
7
Antitumor Activities of Interleukin-12 in Melanoma.白细胞介素-12在黑色素瘤中的抗肿瘤活性
Cancers (Basel). 2022 Nov 14;14(22):5592. doi: 10.3390/cancers14225592.
8
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.随机、双盲、安慰剂对照、全球 III 期试验：替莫唑胺联合替莫唑胺治疗晚期黑色素瘤。
J Clin Oncol. 2023 Jan 20;41(3):528-540. doi: 10.1200/JCO.22.00343. Epub 2022 Aug 23.
9
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.可切除的早期或转移性（IIIB-IVM1a）黑色素瘤伴可注射疾病的新辅助纳武利尤单抗+ T-VEC 联合治疗：NIVEC 试验研究方案。
BMC Cancer. 2022 Aug 4;22(1):851. doi: 10.1186/s12885-022-09896-4.
10
BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma.BCG 水凝胶促进 CTSS 介导的抗原加工和呈递，从而抑制黑色素瘤转移并延长生存期。
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2021-004133.
Zotero 插件